Calithera Biosciences Inc. (NASDAQ:CALA) shot up 2.8% on Wednesday . The stock traded as high as $3.35 and last traded at $3.35, with a volume of 63,691 shares traded. The stock had previously closed at $3.26.

Several brokerages have recently weighed in on CALA. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Zacks Investment Research cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $10.38.

The stock’s market capitalization is $63.53 million. The company has a 50-day moving average of $3.29 and a 200-day moving average of $4.75.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $0.03. Equities research analysts forecast that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.